Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

Earnings reports, acquisitions, and other news are leading the top stock market stories for Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Praxis Precision Medicines stock was a hot topic after the company announced plans for a fireside chat.


Praxis Precision Medicines (PRAX) Prepares for a Fireside Chat

In a report released yesterday, Yatin Suneja from Guggenheim maintained a Buy rating on Praxis Precision Medicines, with a price target of $540.00....

Praxis Precision Medicines (PRAX) Receives a Buy from Guggenheim

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report) ...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and GoodRx Holdings (GDRX)

Praxis Precision Medicines, Inc. (($PRAX)) announced an update on their ongoing clinical study. Praxis Precision Medicines, Inc. is conducting a cl...

Praxis Precision Medicines Advances Elsunersen Trial for Pediatric Epileptic Encephalopathy

Praxis Precision Medicines, Inc. (($PRAX)) announced an update on their ongoing clinical study. Praxis Precision Medicines, Inc. is conducting a Ph...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$169.80	+3.48%	1.74M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$169.80	+3.5%	1.74M
3
4
5
6

PRAX

PRAX

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel